Investment Highlights

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

What sets us apart:

  • Biotech company developing ground-breaking immunotherapies
  • Lead product lefitolimod (MGN1703): potential blockbuster candidate
  • Targeting indications with high unmet medical needs: Cancer and HIV
  • Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules

• Results from the TEACH (HIV) and IMPULSE (small cell lung cancer) clinical trials with lefitolimod • Completion of patient recruitment for the IMPALA pivotal study (colorectal cancer) • Promising results obtained from pre-clinical combination studies using lefitolimod and EnanDIM® • Forecast for 2017 confirmed [more]

Annual Report 2016
Download PDF

 Quarterly Statement as at 31 March 2017
Download PDF

Half-year Report as at 30 June 2017
Download PDF

August 10, 2017
Half-Year Report as at June 30, 2017


Show complete Corporate Calendar.

September 8 - September 12, 2017

ESMO Annual Meeting, Madrid, Spain

Show complete calendar.





Positive subgroup results IMPULSE study

Press Release

Share Price


Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50

Distribution list

If you would like to receive our press releases, please click here.